Gene Therapy for Mucopolysaccharidosis Type II-A Review of the Current Possibilities.

Article Details

Citation
Copy to clipboard

Zapolnik P, Pyrkosz A

Gene Therapy for Mucopolysaccharidosis Type II-A Review of the Current Possibilities.

Int J Mol Sci. 2021 May 23;22(11):5490. doi: 10.3390/ijms22115490.

PubMed ID
34070997 [ View in PubMed
]
Abstract

Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder based on a mutation in the IDS gene that encodes iduronate 2-sulphatase. As a result, there is an accumulation of glycosaminoglycans-heparan sulphate and dermatan sulphate-in almost all body tissues, which leads to their dysfunction. Currently, the primary treatment is enzyme replacement therapy, which improves the course of the disease by reducing somatic symptoms, including hepatomegaly and splenomegaly. The enzyme, however, does not cross the blood-brain barrier, and no improvement in the function of the central nervous system has been observed in patients with the severe form of the disease. An alternative method of treatment that solves typical problems of enzyme replacement therapy is gene therapy, i.e., delivery of the correct gene to target cells through an appropriate vector. Much progress has been made in applying gene therapy for MPS II, from cellular models to human clinical trials. In this article, we briefly present the history and basics of gene therapy and discuss the current state of knowledge about the methods of this therapy in mucopolysaccharidosis type II.

DrugBank Data that Cites this Article

Drugs